An observational study in Acute Coronary Syndrome, Acute Myocardial Infarction and Unstable Angina, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Seoul National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Acute Coronary Syndrome by Seoul National University Hospital — none open to participants now, none under way, none of them phase 3. Acute Coronary Syndrome · Seoul National University Hospital.
Among the 11 studies in Acute Coronary Syndrome by Seoul National University Hospital, this one is the only one that started in 2017, is one of 9 observational ones, and was the 9th registered.
1,489 studies on the registry are indexed under Acute Coronary Syndrome; 271 are open to participants now.
Browse Acute Coronary Syndrome studies →None of the 11 studies in Acute Coronary Syndrome by Seoul National University Hospital is open now. The open studies under Acute Coronary Syndrome, anywhere →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2017.
This study's enrollment of 56 is below the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 2,055 across the 2 interventional studies, 1,533 across the 9 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Acute Coronary Syndrome by Seoul National University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1 month. VerifyNow® and Global thrombosis test were performed at day 2 and 1 month after administration of study drugs. The investigators compared aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU), occlusion time (OT) which reflects shear stress-induced thrombotic activity, and lysis time (LT) which showed endogenous lytic activity between the two strategies at both time points.
Fifty-six patients from 452 patients who underwent percutaneous coronary intervention (PCI) due to ACS in Seoul National University Bundang Hospital. ( April 2017\~ January 2018)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
Occlusion time
Global thrombosis test
Time frame: 1 month
Lysis time
Global thrombosis test
Time frame: 1 month
Occlusion time
Global thrombosis test
Time frame: Day 2
Lysis time
Global thrombosis test
Time frame: Day 2
P2Y12 reaction unit
VerifyNow test
Time frame: Day 2 and 1 month
Aspirin reaction unit
VerifyNow test
Time frame: Day 2 and 1 month
major adverse cardiovascular outcome
composites of cardiac death, myocardial infarction and target lesion revascularization
Time frame: 1 month
BARC bleeding
ARC definition
Time frame: 1 month
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2017 to primary completion in Jan 2018, 8 months.
Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 8 months is below that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →